HRP20030875A2 - Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases - Google Patents
Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases Download PDFInfo
- Publication number
- HRP20030875A2 HRP20030875A2 HR20030875A HRP20030875A HRP20030875A2 HR P20030875 A2 HRP20030875 A2 HR P20030875A2 HR 20030875 A HR20030875 A HR 20030875A HR P20030875 A HRP20030875 A HR P20030875A HR P20030875 A2 HRP20030875 A2 HR P20030875A2
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- cyano
- oxo
- dihydro
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27995601P | 2001-03-29 | 2001-03-29 | |
PCT/US2002/009497 WO2002079149A2 (en) | 2001-03-29 | 2002-03-26 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030875A2 true HRP20030875A2 (en) | 2004-08-31 |
Family
ID=23071059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030875A HRP20030875A2 (en) | 2001-03-29 | 2002-03-26 | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Country Status (26)
Country | Link |
---|---|
US (1) | US6809102B2 (es) |
EP (1) | EP1373221A4 (es) |
JP (1) | JP2005504725A (es) |
KR (1) | KR20030086327A (es) |
CN (1) | CN1507435A (es) |
AR (1) | AR034585A1 (es) |
BG (1) | BG108180A (es) |
BR (1) | BR0208405A (es) |
CA (1) | CA2442482A1 (es) |
CZ (1) | CZ20032645A3 (es) |
EE (1) | EE200300474A (es) |
HR (1) | HRP20030875A2 (es) |
HU (1) | HUP0400350A3 (es) |
IL (1) | IL157441A0 (es) |
IS (1) | IS6967A (es) |
MX (1) | MXPA03008634A (es) |
NO (1) | NO20034300L (es) |
PE (1) | PE20021013A1 (es) |
PL (1) | PL373759A1 (es) |
RU (1) | RU2003130961A (es) |
SK (1) | SK11062003A3 (es) |
TW (1) | TWI228416B (es) |
UY (1) | UY27232A1 (es) |
WO (1) | WO2002079149A2 (es) |
YU (1) | YU75803A (es) |
ZA (2) | ZA200306648B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
SI1847534T1 (sl) * | 2001-12-11 | 2011-10-28 | Kyowa Hakko Kirin Co Ltd | Tiadiazolinski derivati za zdravljenje raka |
BRPI0408150A (pt) * | 2003-03-07 | 2006-03-21 | Astrazeneca Ab | composto, seu uso e processo para preparação do mesmo, métodos para tratamento ou profilaxia de cáncer e para produção de um efeito inibidor do ciclo celular (anti - proliferação celular) em um animal de sangue quente e composição farmacêutica |
AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
CA2522594C (en) | 2003-04-18 | 2012-01-24 | Kyowa Hakko Kogyo Co., Ltd. | Mitotic kinesin inhibitor |
CN1802361A (zh) * | 2003-06-10 | 2006-07-12 | 协和发酵工业株式会社 | 噻二唑啉衍生物 |
WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
US20050282838A1 (en) * | 2003-10-16 | 2005-12-22 | Shyamlal Ramchandani | Compounds, compositions, and methods |
US20070287703A1 (en) * | 2004-07-22 | 2007-12-13 | Astrazeneca Ab | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer |
AU2005273705B8 (en) * | 2004-08-18 | 2010-01-28 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
EP1870404A4 (en) * | 2005-03-22 | 2010-07-14 | Kyowa Hakko Kirin Co Ltd | MEANS FOR THE TREATMENT OF A HEMATOPOIETIC TUMOR |
CA2602397A1 (en) * | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for solid tumor |
WO2006137490A1 (ja) * | 2005-06-24 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 再狭窄治療剤 |
DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
KR970706823A (ko) | 1994-11-16 | 1997-12-01 | 멀닉스 캐슬린 피. | 디히드로피리미딘과 그 사용법(dihydropyrimidines and uses thereof) |
WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
EP1021185A4 (en) | 1996-05-16 | 2005-09-07 | Synaptic Pharma Corp | DIHYDROPYRIMIDINES AND THEIR JOBS |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
AU7975998A (en) | 1997-06-18 | 1999-01-04 | Merck & Co., Inc. | Alpha 1aadrenergic receptor antagonists |
US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
WO1999050440A2 (en) | 1998-04-01 | 1999-10-07 | Yale University | Method to identify modulators of survivin - tubulin interaction |
US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
KR20050049562A (ko) | 1999-10-27 | 2005-05-25 | 싸이토키네틱스, 인코포레이티드 | 퀴나졸리논을 사용하는 방법 및 조성물 |
US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-26 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en active Search and Examination
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Withdrawn
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 PL PL02373759A patent/PL373759A1/xx not_active Application Discontinuation
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0400350A3 (en) | 2005-06-28 |
BR0208405A (pt) | 2004-03-30 |
PE20021013A1 (es) | 2002-11-10 |
ZA200306648B (en) | 2004-11-26 |
NO20034300D0 (no) | 2003-09-26 |
KR20030086327A (ko) | 2003-11-07 |
CA2442482A1 (en) | 2002-10-10 |
HUP0400350A2 (hu) | 2005-01-28 |
US20030008888A1 (en) | 2003-01-09 |
ZA200307320B (en) | 2004-12-20 |
JP2005504725A (ja) | 2005-02-17 |
WO2002079149A3 (en) | 2003-02-27 |
TWI228416B (en) | 2005-03-01 |
WO2002079149A2 (en) | 2002-10-10 |
RU2003130961A (ru) | 2005-04-10 |
US6809102B2 (en) | 2004-10-26 |
UY27232A1 (es) | 2002-11-29 |
CN1507435A (zh) | 2004-06-23 |
NO20034300L (no) | 2003-11-07 |
BG108180A (en) | 2004-09-30 |
YU75803A (sh) | 2006-05-25 |
EP1373221A2 (en) | 2004-01-02 |
PL373759A1 (en) | 2005-09-05 |
EE200300474A (et) | 2003-12-15 |
EP1373221A4 (en) | 2004-09-29 |
MXPA03008634A (es) | 2003-12-08 |
SK11062003A3 (sk) | 2004-08-03 |
IL157441A0 (en) | 2004-03-28 |
AR034585A1 (es) | 2004-03-03 |
CZ20032645A3 (cs) | 2004-06-16 |
IS6967A (is) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6900214B2 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
HRP20030875A2 (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
JP5701758B2 (ja) | Hdm2配位子としてのピロリジン−2−オン | |
JP4394442B2 (ja) | 抗炎症剤として有用なスピロ−ヒダントイン化合物 | |
CA2442455A1 (en) | A method of treating proliferative diseases using eg5 inhibitors | |
JP2004256550A (ja) | 化合物 | |
CA2547080A1 (en) | Heterocyclic protein kinase inhibitors and uses thereof | |
JP2019515932A (ja) | チロシンキナーゼbcr−abl阻害剤としての新規複素環化合物 | |
KR20190027383A (ko) | 아폽토시스 억제제 | |
JP2017512796A (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
CN112313207B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
AU2002258636A1 (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
AU2002303169A1 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
WO2024151833A1 (en) | Spiro derivatives as m4 activators/modulators and uses thereof | |
AU2002248724A1 (en) | A method of treating proliferative diseases using Eg5 inhibitors | |
Mohareb et al. | Heterocyclic synthesis with ethyl α‐(3‐carbamoyl‐4, 5, 6, 7‐tetrahydrobenzo [b] thiophen‐2‐ylhydrazono) acetates: An expeditious synthetic approach to polyfunctionally substituted pyran, pyridine, and pyridazine derivatives | |
MX2011002676A (es) | Pirrolidin-2-onas como ligandos hdm2. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20050209 Year of fee payment: 4 |
|
OBST | Application withdrawn |